


FDA Perspective on Validation of Hepatitis In Vitro Diagnostic Assays

Maria (Ines) Garcia, Ph.D. Maria.Garcia@fda.hhs.gov

Assistant Director General Viral and Hepatitis

Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health Food and Drug Administration

Risk Based Regulation of IVDs



Class I - Low likelihood of harm register & list (21CFR §807) General Controls

Class II - Moderate likelihood of harm or risk can be mitigated Special Controls HDV?

Class III - High or unknown likelihood of harm Significant Risk Pre-market Approval

PreMarket Data Requirements



• Analytical performance measures

- Precision (repeatability, reproducibility)
- Accuracy
- Reactivity (inclusivity)
- Sensitivity, Limit of Detection
- Specificity (interference, cross-reactivity)
- Sample type / matrix
- Sample preparation / conditions
- Performance around the LLoQ and ULoQ, 'cutoffs'
- Linearity
- Potential for carryover, cross-hybridization
- Stability
- Studies and specifications may vary depending on technology or other unique device characteristics
- Similar for Class II and Class III
- Qsub Program Requests for Feedback and Meetings for Medical Device Submissions: <u>The Q-Submission Program | FDA</u>



What Is Different In Class III and Class II Device Evaluation

- Manufacturing section: Complete study reports and documentation are required for Class III submissions. Similar studies are conducted but are not included in the FDA submission for Class II.
- Pre-approval inspection (GMP compliance) only for Class III (standard manufacturer inspections are unchanged).
- BIMO (bioresearch monitoring visit to clinical and/or sponsor sites) for Class III submissions only.
- Post-approval: Requirements for annual reports for Class III approval, not for Class II clearance.
- Validation studies should test multiple lots in performance studies in Class III submissions.
- Stability protocols for Class III may differ from Class II submission and may include additional information.



Thank you Maria.Garcia@fda.hhs.gov